

The American Journal of Human Genetics, Volume 108

Supplemental information

**Bayesian model comparison for
rare-variant association studies**

Guhan Ram Venkataraman, Christopher DeBoever, Yosuke Tanigawa, Matthew Aguirre, Alexander G. Ioannidis, Hakhamanesh Mostafavi, Chris C.A. Spencer, Timothy Poterba, Carlos D. Bustamante, Mark J. Daly, Matti Pirinen, and Manuel A. Rivas

Supplemental Figures




Figure S1. From array to exome. Scatterplot showing the increase in number of protein-altering variants in genes used in the analysis when comparing array (x-axis) to exome (y-axis) data. Data is taken from MRP calculations across 35 biomarker traits within the UK Biobank. Color shows density of points as according to colorbar (right).




Figure S2. *ALPL* gene plot. Gene plot showing variants for which MPC pathogenicity information was incorporated, resulting in a power gain for *ALPL* gene that encodes alkaline phosphatase; for the Alkaline phosphatase phenotype, the incorporation of this information resulted in a $\log_{10}\text{BF}$ gain of 34 (**Table S2**).




Figure S3. Comparisons of $-\log_{10} p$ -values: MRP with independent effects model across variants, SKAT. Correlation coefficient is 0.99. Line shown is $y = x$.




Figure S4. Comparisons of $-\log_{10} p$ -values: MRP with similar effects model across variants, burden test. Correlation coefficient is 0.93. Line shown is $y = x$.




Figure S5. From single-variant and single-phenotype to multiple-variant and multiple-phenotype gene discovery: when only a single variant has true effect. ROC curves for detecting simulated gene association to any of the phenotypes using single variant/single phenotype association (turquoise) to multiple-variant and multiple-phenotype association (pink). If only a single variant has true effect, adding data from multiple variants demonstrates no improvement (and sometimes detriment).







Figure S6. From single-variant and single-phenotype to multiple-variant and multiple-phenotype gene discovery: when phenotypes are independent. ROC curves for detecting simulated gene association to any of the phenotypes using single variant/single phenotype association (turquoise) to multiple-variant and multiple-phenotype association (pink). If phenotypes are truly independent, there may still be information across the genotypes that allows for improvement of performance, but not as drastic of an improvement as found when there is a clear correlation structure across phenotypes.


Bone and Joint



Diabetes







Figures S7-11. Manhattan plots showing \log_{10} BF under an independent effects variant model amongst protein-altering variants for 5 categories across 35 biomarkers. These include: Bone and Joint, Diabetes, Hormone, Liver, and Renal traits. Scale is logarithmic after \log_{10} BF ≥ 10 . Genes found in Sinnott-Armstrong, et.al.¹ are annotated in grey, whereas the other genes are annotated in black. Colors indicate different traits as indicated at the bottom of the plots.




Figure S12. LD-score regression-based genetic correlation plots of all 35 biomarkers included in the multi-trait analyses. The traits are ordered by hierarchical clustering. Blue implies positive and red implies negative correlation coefficients as indicated by the colorbar (right).

Supplemental Tables

| Trait | gene | Number of PAVs, array | log ₁₀ BF, array | Number of PAVs, exome | log ₁₀ BF, exome | log ₁₀ BF Difference |
|---------------------------|----------------|-----------------------|-----------------------------|-----------------------|-----------------------------|---------------------------------|
| Total bilirubin | <i>UGT1A7</i> | 5 | 1.2 | 247 | 213 | 211.8 |
| Direct bilirubin | <i>UGT1A7</i> | 5 | 0.6 | 228 | 133 | 132.4 |
| Lipoprotein A | <i>PLG</i> | 57 | 38.9 | 583 | 165 | 126.1 |
| SHBG | <i>SHBG</i> | 7 | 2.7 | 284 | 114 | 111.3 |
| LDL cholesterol | <i>PCSK9</i> | 94 | 4.0 | 759 | 99 | 95.0 |
| Total bilirubin | <i>MROH2A</i> | 33 | 4.6 | 1649 | 85.8 | 81.2 |
| Apolipoprotein B | <i>PCSK9</i> | 94 | 3.1 | 756 | 80.7 | 77.6 |
| Cholesterol | <i>PCSK9</i> | 94 | 4.0 | 760 | 80.9 | 76.9 |
| IGF-1 | <i>GH1</i> | 5 | 2.1 | 301 | 55.1 | 53.0 |
| Direct bilirubin | <i>MROH2A</i> | 33 | 2.9 | 1497 | 55.7 | 52.8 |
| Gamma glutamyltransferase | <i>GGT1</i> | 5 | 0.008 | 545 | 52.1 | 52.1 |
| Triglycerides | <i>ANGPTL3</i> | 7 | -0.02 | 337 | 39.9 | 39.9 |
| Cholesterol | <i>ANGPTL3</i> | 7 | -0.6 | 337 | 34.3 | 34.9 |
| Cholesterol | <i>APC</i> | 1409 | -34.7 | 1882 | -0.5 | 34.2 |
| LDL cholesterol | <i>APC</i> | 1410 | -33.7 | 1882 | -0.5 | 33.2 |
| Apolipoprotein B | <i>APC</i> | 1405 | -32.7 | 1876 | -0.7 | 32.0 |
| Total bilirubin | <i>UGT1A5</i> | 12 | 2.0 | 225 | 33 | 31.0 |

| | | | | | | |
|------------|-----|------|-------|------|------|------|
| Albumin | APC | 1366 | -31.6 | 1807 | -1.2 | 30.4 |
| Vitamin D | APC | 1379 | -29.8 | 1828 | 0.2 | 30.0 |
| Creatinine | APC | 1411 | -31.4 | 1883 | -1.9 | 29.5 |

Table S1. Genes with considerable power gain in exome data as compared to array data.

| Trait | Gene | Number of PAVs | log ₁₀ BF without MPC | Number of MPC-augmented PAVs | Number of pLI-augmented PAVs | log ₁₀ BF with MPC | log ₁₀ BF Difference |
|----------------------------|-----------------|----------------|----------------------------------|------------------------------|------------------------------|-------------------------------|---------------------------------|
| Alkaline phosphatase | <i>ALPL</i> | 198 | 126 | 93 | 0 | 160 | 34 |
| Lipoprotein A | <i>LPA</i> | 512 | 109 | 20 | 0 | 114 | 5 |
| Apolipoprotein A | <i>APOA1</i> | 102 | 11.7 | 30 | 0 | 15.7 | 4 |
| HDL cholesterol | <i>APOA1</i> | 103 | 9.36 | 30 | 0 | 13.2 | 3.84 |
| Aspartate aminotransferase | <i>SLC30A10</i> | 112 | 3.76 | 50 | 6 | 7.2 | 3.44 |
| Phosphate | <i>ALPL</i> | 192 | 10.9 | 91 | 0 | 14.3 | 3.4 |
| Lipoprotein A | <i>IGF2R</i> | 763 | 29.8 | 153 | 27 | 33.1 | 3.3 |
| HDL cholesterol | <i>SCARB1</i> | 220 | 5.45 | 66 | 0 | 8.29 | 2.84 |
| Apolipoprotein B | <i>APOE</i> | 142 | 5.48 | 60 | 0 | 8.27 | 2.79 |
| Alanine aminotransferase | <i>SLC30A10</i> | 112 | 2.94 | 50 | 6 | 5.56 | 2.62 |

Table S2. Power comparison between variant annotation-based MRP and MPC/pLI-augmented MRP analyses across 35 biomarkers. We see considerable gains in power in several gene/trait combinations.

| # Studies | # Phenotypes | Phenotype Specification | Genetic Datatype | Average Runtime (DD:HH:MM) |
|-----------|--------------|-------------------------|------------------|----------------------------|
| Single | Single | Binary | Array | 00:00:02 |
| Single | Single | Quantitative | Array | 00:00:08 |
| Multiple | Single | Binary | Array | 00:00:20 |
| Multiple | Single | Quantitative | Array | 00:00:40 |
| Single | Single | Binary | Exome | 00:02:00 |
| Single | Single | Quantitative | Exome | 00:08:00 |
| Multiple | Single | Binary | Exome | 00:05:00 |
| Multiple | Single | Quantitative | Exome | 01:00:00 |
| Single | Multiple | Binary | Array | 00:02:00 |
| Single | Multiple | Quantitative | Array | 00:05:00 |
| Single | Multiple | Binary | Exome | 02:00:00 |
| Single | Multiple | Quantitative | Exome | 05:00:00 |

Table S3. Computation times for various MRP analyses. One node with 16 cores and 200 GB RAM was used.

Supplemental References

1. Sinnott-Armstrong, N., Tanigawa, Y., Amar, D., Mars, N., Benner, C., Aguirre, M., Venkataraman, G.R., Wainberg, M., Ollila, H.M., Kiiskinen, T., et al. (2021). Genetics of 35 blood and urine biomarkers in the UK Biobank. *Nat. Genet.* 53, 185–194.